Breast cancer is the foremost common malignancy among the female population around the world. Female breast cancer incidence rates have increased since 1980, slowed in 1990, the rate of increase have leveled off since 2001. In spite of the advances in the early detection, treatment, surgery and radiation support, almost 70% of the patients develop metastasis and die of the disease. Around 10% of the patients when diagnosed with breast cancer have metastases. Survival among the breast cancer patients have increased due to the introduction of novel single agent, combination of chemotherapeutic agents and targeted biologic agents, which is breast cancer specific. The staging of tumor-node-metastasis is significant for the prognosis and treatment. Predominantly the combination of chemotherapeutic regimen is given to improve the rate of clinical benefit and the overall survival rate. Novel mono-therapeutic options are being used often in metastatic setting as they will not be able to endure the toxicity of the combination regimen. Usually, endocrine therapy is recommended for hormone-responsive breast cancer due to efficacy and favorable side effect profile but chemotherapy becomes an option when endocrine therapy fails. This review summarizes the newer therapeutic options for early breast cancer and advanced breast cancer that are pretreated heavily on other chemotherapeutic agents. Further it provides monotherapies and other emerging novel combination regime which can be opted for first line or second line setting.

Key words: Breast cancer, metastasis, novel monotherapy, combination regimen, clinical benefit rate

Breast cancer is a malignant proliferation of epithelial cell lining the ducts or lobules of the breast, which may have diverse outcomes and responses to treatment depending on the early diagnosis. This is the most common cancer in woman in many developed and developing countries. Breast cancer is the leading cause of cancer deaths in females between 20 and 59 years[1]. Early accurate diagnosis is important for optimizing the treatment and potential for cure. During the last decades, breast cancer survival has increased considerably[2,3] due to earlier diagnosis and increasing use of adjuvant and neoadjuvant therapies but around 30-70% of the patients eventually develop recurrence and die of metastasis every year. Improved treatment options offer a better prognosis for the patients with breast cancer.

The possibility of breast cancer is augmented with the increasing age, past medical history of uterus cancer, ovarian cancer, and family history of breast cancer.

Postmenopausal hormone replacement therapy may also direct to breast cancer. Patients who had prior treatment for breast cancer have 30-50% chance of developing cancer in the contra lateral breast which can be reduced by adjuvant endocrine therapy for minimum 5 years. Several genetic, hormonal, and environmental factors are involved in the development of breast cancer.

Chemotherapy treatment during early stage breast cancer has shown to extend the survival. Chemotherapeutic option with anthracyclines or taxanes is considered to be the most effective in breast cancer. Almost 70% of the patients with metastatic breast cancer have human receptor (HR) positive tumors, which are responsive to adjuvant hormone therapy and helps in prolonging the disease free survival. Chemotherapy is the only treatment option for rapidly progressing metastatic breast cancer (MBC) and various classes of drugs along with their mechanism, available for the treatment as monotherapy is represented in fig. 1. Treatment failure in metastatic setting occurs due to the resistance to the chemotherapeutic agents which may be due
to the prior exposure to these agents. No standard monotherapy or combination palliative chemotherapy is existing for patients who are pretreated with anthracyclines or taxanes. The median survival rate of the patient with metastasis is within the range of 3 years. When patients with metastasis are seen then the aim of the treatment is palliative care providing mental support and increasing the median survival. This article summarizes some of the newer therapeutic options currently available for the treatment of MBC.

**NOVEL MONOTHERAPEUTIC OPTIONS AVAILABLE FOR THE TREATMENT**

**Eribulin mesylate:**
Eribulin mesylate is a non-taxane, synthetic analog of halichondrin B isolated from a sea sponge. Eribulin has a mechanism of action that is distinct from those of the other tubulin targeting agents and it inhibits the microtubule growth phase causing tubulin sequestration into the non-productive aggregates. It causes irreversible mitotic block and apoptosis. It was hypothesized that Eribulin may be shown to have efficacy in cancer related to tubulin targeted agents. Eribulin is given to patients who are having metastatic breast cancer and pretreated with an anthracycline or a taxane. EMBRACE trial was conducted to know the effect of Eribulin monotherapy versus the treatment of physician choice in patients with MBC, which concluded that the median progression free survival was 3.7 months, clinical benefit rate was 23%, overall survival rate was 58%. Cotes et al. conducted a phase 2 study of the halichondrin B analog in patients with advanced MBC previously treated with an anthracyclines, taxanes, and capecitabine. The study results had reported that the objective response rate was 11.5% and clinical benefit rate of 17.2% with manageable tolerability profile (Table 1).
TABLE 1: MONOTHERAPY USED IN VARIOUS TRIALS FOR THE TREATMENT OF METASTATIC BREAST CANCER

<table>
<thead>
<tr>
<th>Name of the drug</th>
<th>Name of the trial</th>
<th>No. of patients</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Outcomes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eribulin mesylate</td>
<td>EMBRACE trial 2011</td>
<td>762</td>
<td>Age of 18 years and older, histologically confirmed with breast cancer, have taken 2-5 previous chemotherapeutic regimen like an anthracycline or a taxane, progression within 6 months of the last chemotherapy, adequate bone marrow, liver, renal function</td>
<td>Previous participation in an Eribulin trial, use of any investigational drug within 4 weeks of the study, prior treatment with chemotherapy, radiation, trastuzumab or hormonal therapy within 3 weeks of the study, untreated brain metastasis, preexisting neuropathy of grade 2 or higher</td>
<td>Significant improvement in overall survival, manageable toxic effects, significant improvement in the objective response rate, progression free survival</td>
<td>Cortes et al. [5] 2011</td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>HERA trial 2011</td>
<td>5102</td>
<td>HER2 positive patients who had completed loco regional therapy, received at least 4 cycles of chemotherapy</td>
<td>Metastasis, previous treatment for invasive malignant disease, previous or concurrent malignant disease other than basal cell carcinoma of the skin or in situ cervical cancer, pregnancy or lactation, use of other investigational drugs within 30 days, serious medical illness including cardiac failure</td>
<td>Overall incidence of cardiac events is low, treatment with adjuvant trastuzumab for 1 year after chemotherapy is associated with significant clinical benefit at 4 year median follow up</td>
<td>Gianni et al. [12] 2011</td>
</tr>
<tr>
<td>Fulvestrant</td>
<td>CONFIRM trial 2010</td>
<td>736</td>
<td>Postmenopausal with locally advanced or metastatic breast cancer previous treatment with antiestrogen or an aromatase inhibitor as a first line therapy</td>
<td>Liver or lung metastasis, brain-leptomeningeal metastasis more than one chemotherapy or endocrine therapy</td>
<td>Fulvestrant 500 mg prolongs progression free survival over low dose. It did not cause increased clinical benefit rate</td>
<td>Leo et al. [9] 2010</td>
</tr>
<tr>
<td>Eribulin</td>
<td>-</td>
<td>299</td>
<td>Age&gt;18 years, histologically confirmed with breast cancer, 2-5 prior chemotherapeutic regimen with anthracyclines or paclitaxel, adequate liver, bone marrow, kidney function HER2 positive patients must have received trastuzumab, ER2 positive patients should have received endocrine therapy</td>
<td>Hormonal therapy within 1 week, chemotherapy or radiation within 2 weeks of starting of Eribulin, prior treatment with Eribulin, mitomycin, nitrosourea, progression of brain metastasis cardiovascular impairment, neuropathy of grade 2, pregnancy, breast feeding, HIV, hypersensitivity to halichondrin B or derivatives</td>
<td>Objective response rate, clinical benefit rate was noted</td>
<td>Cortes et al. [6] 2010</td>
</tr>
<tr>
<td>Olaparib</td>
<td>-</td>
<td>54</td>
<td>Patients of more than 18 years, MBC, mutation of BRCA1/BRCA2, ECOG performance scale of 0-2, life expectancy of 16 weeks</td>
<td>Anticancer therapy in 28 days, brain or CNS metastasis, more than grade 2 toxicity</td>
<td>Favorable therapeutic index in those who have genetic loss of function BRCA1, BRCA2</td>
<td>Tutt et al. [15] 2010</td>
</tr>
<tr>
<td>Pertuzumab</td>
<td>-</td>
<td>79</td>
<td>Age of more than 18 years, performance status of 80%, MBC, adequate hematologic, renal, hepatic function</td>
<td>Major surgery, pulmonary metastasis with lymphangitis or dyspnea at rest, LVEF less than 50%, pregnant, lactating</td>
<td>The single agent Pertuzumab in HER2 negative breast cancer was not beneficial in the patients with metastasis</td>
<td>Gianni et al. [14] 2010</td>
</tr>
</tbody>
</table>

**Fulvestrant:**
It is an estrogen receptor (ER) antagonist that down regulates the circulating ERs. It is currently used in the treatment of postmenopausal women with advanced breast cancer even with prior endocrine treatment. It acts by ER dimerization causing rapid degradation leading to the loss of cellular ER. The drug was approved by USFDA in 2002. CONFIRM
It is the first antiHER2 therapy reported that the median duration of response was 19.4 months for 500 mg and 16.4 months for 250 mg of fulvestrant (Table 1).

**Trastuzumab:**
It is a humanized monoclonal antibody directed against extracellular domains of the HER2 receptor and it dramatically improved the outcomes in patients with HER2 over expressing (HER2 positive) breast cancer. It binds to an epitope in the HER2 receptor that cause uncoupling of HER2–HER3 heterodimers thereby inhibiting antibody dependent cell-mediated cytotoxicity. It is the first antiHER2 therapy approved by USFDA in 1998. Recently concluded HERA trial (2011) reported that disease free survival in the patients treated with 1 year trastuzumab was 78.6% as compared with the observation group 72.2% while there was no significant difference in the overall survival rate in the both groups. NOAH Trial reported the addition of trastuzumab as neoadjuvant significantly improved the event free survival in HER2 positive breast cancer patients by 71% versus 56% without trastuzumab (Table 1).

**Olaparib:**
It acts by inhibiting enzyme poly ADP ribose polymerase. It is one of the first PARP inhibitor. Olaparib 400 mg twice daily was found to be active in patients with BRCA1 or BRCA2 mutations, MBC which was resistant to conventional chemotherapy. Tutt et al. concluded that olaparib 400 mg twice daily had better progression free survival, the objective response rate than 100 mg twice daily. The objective response rate with 400 mg olaparib group was 41% and with 100 mg group was 22% (Table 1).

**Pertuzumab:**
It binds to HER2 at the dimerization domain, thereby inhibiting its ability to form dimmers, bind competitively to the intracellular adenosine tri phosphate binding site of HER. Gianni et al. concluded that in patients treated with loading dose of pertuzumab (arm A) the median duration of clinical benefit was 36.5 weeks and those treated with no loading dose of pertuzumab (arm B) the median duration of clinical benefit was 33-36 weeks. Median time to treatment failure was 6.3 weeks in arm A and 6 weeks in arm B (Table 1).

**CURRENT COMBINATION REGIMEN(S) FOR THE TREATMENT OF BREAST CANCER**

**Bevacizumab and taxanes:**
Bevacizumab is humanized monoclonal antibody that specifically inhibits vascular endothelial growth factor. It is a key mediator of angiogenesis. Bevacizumab is used for the treatment of metastatic breast cancer, colorectal cancer, and non-small cell lung cancer. It is approved as the first line treatment in glioblastoma multiforme. It was approved by USFDA in 2004. It was also granted approval to be used in combination with interferon alfa for the treatment of metastatic renal cell carcinoma. Smith et al. reported the overall response rate of 47% and median time to progression of 7.2 months with median overall survival of 19.5 months. Smith et al. reported that this combination regimen has improved the time to progression, overall response rate and had less adverse event (Table 2). Miles et al. reported that the regimen increased the progression free survival when combined with docetaxel.

**Bevacizumab, everolimus, and lapatinib:**
Everolimus inhibits mammalian target of rapamycin complex 1 (mTORC1) which plays an essential role in protein synthesis thereby reducing cell proliferation, tumor growth, and angiogenesis. It is also approved for treating patients with progressive neuroendocrine tumors in the pancreas, which cannot be surgically removed and in metastatic pancreatic cancer. Lapatinib is a 4-anilinoquinazoline kinase inhibitor of intracellular tyrosine kinase domains of epidermal growth factor receptor. It also inhibits HER2 and HER1 receptor tyrosine kinase and it was approved in 2007 by USFDA. Minkwitz et al. reported the treatment of chemotherapy with bevacizumab had 19.4% discontinuations with everolimus the discontinuation was 24.1% and with lapatinib the discontinuation was 34.5%. Treatment was discontinued in patients with lapatinib 1250 mg due to the side effects (Table 3).

**Cabazitaxel and capecitabine:**
Cabazitaxel is a novel tubulin binding taxoid. It has a safety profile in docetaxel or paclitaxel resistant breast cancer. Recently in the year 2010, this drug was approved by USFDA for the treatment of metastatic breast cancer patients. It is also used in the treatment of metastatic hormone refractory prostate cancer. Villanueva et al. reported that the median duration
TABLE 2: COMBINATION REGIMENS USED IN VARIOUS TRIAL FOR THE TREATMENT OF MBC AND ITS OUTCOME

<table>
<thead>
<tr>
<th>Name of the regimen</th>
<th>Name of the trial</th>
<th>No of patients</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capecitabine and vinorelbine</td>
<td></td>
<td>50</td>
<td>Women aged 18-75, histologically confirmed with breast cancer, previously treated with anthracyclines or a taxane, adequate renal, hepatic, hematologic function, prior hormonal therapy or prior radiation therapy</td>
<td>Pregnant, lactating, history of other cancer within past 5 years except non melanoma skin cancer, in situ carcinoma of the cervix</td>
<td>Combination chemotherapy is effective and safe for patients who are previously treated with anthracyclines, taxanes. Safe and tolerable as a second line treatment in the patients with metastatic breast cancer</td>
<td>Mao et al. [33] 2011</td>
</tr>
<tr>
<td>Cabazitaxel and capecitabine</td>
<td></td>
<td>33</td>
<td>Age of above 18 years, histologically confirmed breast cancer, adequate renal, hepatic, hematological function, at least one measurable lesion, prior exposure to anthracyclines or taxanes</td>
<td>-</td>
<td>The overall response rate was 23.8%. It showed activity and favorable safety profile in patients pretreated with anthracyclines or taxanes across all dose levels</td>
<td>Villanueva et al. [42] 2011</td>
</tr>
<tr>
<td>Trastuzumab with vinorelbine and docetaxel</td>
<td></td>
<td>284</td>
<td>Eligible patients with the age of 18-75 years, histologically confirmed with breast cancer, HER2 positive, measurable or non measurable disease, performance status of less than 2, adequate bone marrow, renal, liver, cardiac function, life expectancy of more than 12 weeks</td>
<td>Brain metastasis, dyspnea, second primary malignancy, serious concomitant illness</td>
<td>The trial didn’t show any superiority of any drug in terms of efficacy. The combination with vinorelbine had fewer toxicity profiles as compared with the docetaxel. Median time to treatment failure for docetaxel was 5.6 months versus 7.7 months for Vinorelbine</td>
<td>Anderson et al. [34] 2011</td>
</tr>
<tr>
<td>Trastuzumab and docetaxel with trastuzumab, docetaxel, carboplatin</td>
<td>BCIRG 007 Study 2011</td>
<td>263</td>
<td>MBC patients with HER2 positive, between age limit of 18-75, karnofsky performance status of less than 60%, adequate liver, renal, cardiac, hematological function, prior taxane-based or trastuzumab-based or anthracycline-based adjuvant therapy</td>
<td>Brain or leptomeningeal metastasis, prior congestive heart failure, myocardial infection in the preceding year, unstable angina, grade 3 cardiac arrhythmia, uncontrolled hypertension, active infection, active peptic ulcer, unstable diabetes mellitus, peripheral neuropathy, chronic corticosteroid therapy, serious medical illness, psychiatric condition, invasive malignancy for the past 10 years</td>
<td>Both regimens in the study were highly active and each having a response rate of 72%, time to progression of approximately 10 months and median overall survival exceeding 3 years. Both regimens have similar safety profile, active regimens for patients with HER2 amplified disease</td>
<td>Valero et al. [35] 2010</td>
</tr>
<tr>
<td>Pegylated liposomal doxorubicin and cyclophosphamide</td>
<td></td>
<td>29</td>
<td>Patients with stage 2-3 of age more than 66 years adequate bone marrow, renal, hepatic function, left ventricular ejection fraction of more than 55% ECOG performance status of 0-2, measurable lesions</td>
<td>-</td>
<td>All patients had clinical response with partial response of 62.1%, pathological complete response 3.4%. Treatment was well tolerated with no grade 3, 4 toxicities, but have limited activity in pre operative setting</td>
<td>Dellapasqua et al. [32] 2011</td>
</tr>
<tr>
<td>Paclitaxel and uracil-tegafur</td>
<td>TEGATAX trial 2011</td>
<td>31</td>
<td>Metastatic or locally advanced breast cancer patients of the age more than 18, who are HER2 negative resistant to anthracyclines, at least one radiological measurable lesion, less than 2 regimens during metastasis</td>
<td>Prior treatment with paclitaxel, tegafur, capecitabine, brain metastasis, peripheral neuropathy of more than grade 2</td>
<td>The combination therapy have a significant role in the overall response of 40%, response duration of more than 8 months, clinical benefit of 59%, median survival of 23.5 months, time to disease progression of 9.5 months</td>
<td>Villanueva et al. [49] 2011</td>
</tr>
</tbody>
</table>

Contd...
<table>
<thead>
<tr>
<th>Name of the regimen</th>
<th>Name of the trial</th>
<th>No of patients</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motesanib and paclitaxel</td>
<td>282</td>
<td>HER2 negative locally advanced or metastatic breast cancer patients over 18 years with the ECOG performance of 0-1, adequate organ, hematological function</td>
<td>No significant difference in the objective response rate between motesanib and the placebo group, clinical benefit rate was 66% for motesanib group, a significant improvement of 14%. The combination regimen is not more effective than placebo with paclitaxel for HER2 negative advanced breast cancer</td>
<td>Martin et al. [45] 2011</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iniparib plus chemotherapy</td>
<td>123</td>
<td>Metastatic breast cancer female patients of age more than 18 years, ER negative, PR negative, ECOG performance of 0-5, adequate bone marrow, renal, hepatic function, clinically stable brain metastasis</td>
<td>In iniparib group the clinical benefit rate was 56% which is greater than chemotherapy group. Progression free survival was 5.9 months in iniparib group and 3.6 months in chemotherapy alone. Overall survival was 12.3 months in iniparib group and 7.7 months in chemotherapy alone group. In patients with advance triple negative breast cancer the addition of Iniparib to the chemotherapy improved the clinical benefit rate and the overall survival</td>
<td>Shaughnessy et al. [41] 2011</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tamoxifen and exemestane</td>
<td>TEAM trial 2011</td>
<td>9779</td>
<td>Histologically confirmed estrogen receptor positive, progesterone positive breast cancer who had completed local treatment, invasive tumor with all size without axillary lymph node involvement , no metastasis</td>
<td>Cardiac disease, any other malignancy</td>
<td>No significant difference in the overall survival and the diseases free survival was noted in the patients treated with both regimen</td>
<td>Velde et al. [39] 2011</td>
</tr>
<tr>
<td>Bevacizumab and taxane</td>
<td>2251</td>
<td>Histologically confirmed HER 2 negative metastatic breast cancer patients of more than 18 years, ECOG of 0-2, adequate hepatic, renal, hematologic function</td>
<td>Previous chemotherapy for metastatic breast cancer, peripheral neuropathy of more than grade 2, increased peripheral neuropathy, minor surgery within 24 h, active peptic ulcer, hypertension, pregnancy, lactation</td>
<td>Time to progression was 9.5 months; overall response rate was 52%. The combination chemotherapy is well tolerated and had less adverse event</td>
<td>Smith et al. [21] 2011</td>
<td></td>
</tr>
<tr>
<td>Capecitabine and vinorelbine</td>
<td>72</td>
<td>Age of &gt;18 years, histological confirmation of breast cancer, previous chemotherapy with anthracyclines or taxanes adequate renal, hepatic, cardiac function</td>
<td>Hypersensitivity to fluoropyrimidines more than grade 2 of peripheral neuropathy, serious illness organ allograft, GI disorder, pregnant, lactating women</td>
<td>Response rates varied from 39-70%, suitable treatment regimen for elderly patient of more than 65 years with MBC, acceptable toxicity and efficacy profile</td>
<td>Fan et al. [34] 2010</td>
<td></td>
</tr>
<tr>
<td>Ixabepilone and capecitabine</td>
<td>1221</td>
<td>Metastatic advanced disease, performance scale of more than 70%, life expectancy of more than 12 weeks, prior pretreatment with anthracyclines or taxanes</td>
<td>Pregnancy, lactation, serious illness</td>
<td>Improved progression free survival and overall response rate, safety profile was manageable with appropriate dose modification</td>
<td>Sparano et al. [36] 2010</td>
<td></td>
</tr>
</tbody>
</table>

Contd....
### TABLE 3: MULTIPLE NEWER REGIMENS ON RECENT TRIALS AND ITS OUTCOME

<table>
<thead>
<tr>
<th>Name of the regimen</th>
<th>Name of the trial</th>
<th>No of patients</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bevacizumab, everolimus, lapatinib and neoadjuvant chemotherapy</td>
<td>Gepar Quinto trial 2011</td>
<td>270</td>
<td>Healthy female patients with unilateral or bilateral untreated breast cancer, HER2 negative, age of more than 18 years ECOG performance status of 0-2, adequate renal, hepatic, hematologic function</td>
<td>-</td>
<td>Combination regimen increased the progression free survival while given as first line for MBC as compared with Docetaxel and placebo</td>
<td>Miles et al. [22] 2010</td>
</tr>
<tr>
<td>Lapatinib and paclitaxel</td>
<td>49</td>
<td>Histologic diagnosis of inflammatory breast cancer, tissue over expression of HER2 with or without EGFR, adequate functioning of the organs</td>
<td>Previously treated disease</td>
<td>Clinical benefit was seen after lapatinib monotherapy for 14 days after pretreatment with paclitaxel and lapatinib</td>
<td>Boussen et al. [43] 2010</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel and bevacizumab with or without sunitinib</td>
<td>SABRE-B</td>
<td>HER2 negative MBC with no prior chemotherapy, any prior adjuvant chemotherapy, brain metastasis, ECOG of 0-1, adequate organ function</td>
<td>Uncontrolled hypertension, heart failure, proteinuria, open biopsy, major surgery, significant injury within 28 days of the enrollment</td>
<td>Addition of sunitinib to bevacizumab and paclitaxel is not feasible due to the side effects</td>
<td>Mayer et al. [47] 2010</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel and bevacizumab</td>
<td>736</td>
<td>Histologically confirmed HER2 negative, age of more than 18 years ECOG performance status of 0-2, adequate renal, hepatic, hematologic function</td>
<td>Combination regimen increased the progression free survival while given as first line for MBC as compared with Docetaxel and placebo</td>
<td>Miles et al. [22] 2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxorubicin plus pemetrexed followed by docetaxel</td>
<td>276</td>
<td>Histologically confirmed primary invasive breast cancer, HER 2 over expressing patients with age 18-70 years, staging T2-4a N0-2M0, tumor size of more than 2 cm, adequate cardiac function, life expectancy of more than 6 months</td>
<td>-</td>
<td>Bevacizumab with EC-D was well tolerated (26%) with chemotherapy alone (21.5%). Everolimus and P after EC pretreatment did not have significant difference in the toxic effects. Adding bevacizumab and everolimus to chemotherapy appeared feasible</td>
<td>Minkwitz et al. [26] 2011</td>
<td></td>
</tr>
<tr>
<td>Doxorubicin plus cyclophosphamide followed by docetaxel</td>
<td>1830</td>
<td>Stage 1-3A, T1or T2 disease with one sentinel node with micro metastasis less than 2 mm, prior treatment with mastectomy within 84 days of the study</td>
<td>T4 stage, previously received any prior treatment for breast cancer, history of other malignancy within 5 years, prior anthracyclines or anthracyclines therapy, cardiac dysfunction</td>
<td>AP-D had a CR rate of 14.5% and a PR rate of 45%. AC-D had a complete response rate of 17.6% and a PR of 50.4%. Pathological complete response for AP-D and AC-D was 16.5 and 20.2%, respectively. Both the chemotherapeutic regimen is well tolerated, active as neoadjuvant chemotherapy in early breast cancer. AC-D is active against HR negative tumors than HR positive tumor while the other regimen have almost same efficacy in HR positive and negative tumor</td>
<td>Schneeweiss et al. [53] 2010</td>
<td></td>
</tr>
<tr>
<td>Doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel</td>
<td>270</td>
<td>Histologically confirmed primary invasive breast cancer, HER 2 over expressing patients with age 18-70 years, staging T2-4a N0-2M0, tumor size of more than 2 cm, adequate cardiac function, life expectancy of more than 6 months</td>
<td>An experimental drug if used within 30 days of study, prior anthracycline or antitumor therapy, second primary malignancy of cervix, serious concomitant disorder</td>
<td>There was no significant difference in the 6 year survival for the two arms. The substitution of paclitaxel for cyclophosphamide has shown to be more effective for high risk breast cancer patients</td>
<td>Loesch et al. [59] 2010</td>
<td></td>
</tr>
</tbody>
</table>
Capecitabine is an oral fluoropyrimidine prodrug which is orally administered and converted to 5-fluorouracil at the tumor site via a three-phase enzymatic cascade. After two intermediate steps involving carboxyl esterase I the liver, and cytidine deaminase in the liver/tumor tissue, the final metabolite is converted to 5-fluorouracil by thymidine phosphorylase. It has shown its efficacy in patients who are heavily pretreated with anthracycline or a taxane. Due to its favorable toxicity and efficacy profile it is used frequently in clinical trial of novel drugs as control treatment. Capecitabine can be used as a single agent in patients with advanced breast cancer who are pretreated with anthracycline or taxanes. Capecitabine monotherapy has time to progression (3.1-4.9 months) and the response rate of 20-28% approximately. Mao et al. have reported that the overall clinical benefit rate was 72% and the objective response rate was 26% with median time to progression of 5 months. Fan et al. reported that median time to progression was 7.7 months, median survival of 26.1 months and response rate of 53.8%.

Capecitabine and vinorelbine: Vinorelbine is third generation vinca alkaloid that has significant activity against advanced breast cancer in the first line setting. Capecitabine is an oral fluoropyrimidine precursor which is orally administered prodrug activated in liver and converted to 5-fluorouracil at the tumor site. The inhibition of kinase is different from that of other VEGFR inhibitors. Shaughnessy et al. reported that when iniparib was added to 5-fluorouracil by thymidine phosphorylase. It has shown its efficacy in patients who are heavily pretreated with anthracycline or a taxane. Due to its favorable toxicity and efficacy profile it is used frequently in clinical trial of novel drugs as control treatment. Capecitabine can be used as a single agent in patients with advanced breast cancer who are pretreated with anthracycline or taxanes. Capecitabine monotherapy has time to progression (3.1-4.9 months) and the response rate of 20-28% approximately. Mao et al. have reported that the overall clinical benefit rate was 72% and the objective response rate was 26% with median time to progression of 5 months. Fan et al. reported that median time to progression was 7.7 months, median survival of 26.1 months and response rate of 53.8%.

Capecitabine and ixabepilone: Ixabepilone is a semisynthetic analog of epothilone analog which acts by binding to β tubulin subunits of microtubules leading to induction of tubulin polymerization and disruption of chromosomal segregation that is needed for the completion of mitosis. It ultimately induces apoptosis. It has low susceptibility to common resistance mechanism that is related to anthracyclines or taxanes. Combination of this regimen is mainly used in advanced breast cancer and those patients who are treated prior with anthracycline or taxanes. Sparano et al. reported that the overall response rate of the combination regimen was 43%, time to response was 6.6 weeks, median progression free survival was 6.24 months for the combination as compared with 4.4 months for capecitabine alone.

Exemestane and tamoxifen: Exemestane is a third generation steroidal aromatase inhibitor used for metastatic breast cancer. Exemestane has more efficacy as compared with tamoxifen given alone. Exemestane has currently emerged as the first line treatment option for metastatic breast cancer after a phase 2 randomized trial conducted by the European organization for research and treatment of cancer (EORTC). Exemestane is mainly used in postmenopausal women with early or advanced breast cancer. Velde et al. reported that when 5 years data were taken, no difference was noted in the disease free survival and overall survival in patients with HR positive breast cancer treated with exemestane and tamoxifen but musculoskeletal adverse events were increased with exemestane therapy alone.

Iniparib plus chemotherapy: Iniparib is a poly adenosine diphosphate-ribose polymerase 1 (PARP1) inhibitor. PARP1 regulates the DNA base-excision repair. Now iniparib is recommended for triple negative breast cancer. Iniparib synergizes the cytotoxic and antiproliferative effects of gemcitabine and carboplatin. Shaughnessy et al. reported that when iniparib was added to gemcitabine and carboplatin the clinical benefit rate improved from 34 to 56%, median overall survival from 7.7 months to 12.3 months with median progression free survival from 3.6 to 5.9 months.

Lapatinib and paclitaxel: It is a tyrosine kinase inhibitor and inhibits the cellular proliferation which is overexpressed with HER1 or HER2. It acts intracellularly, binds with cytoplasmatic ATP binding site thereby blocking the phosphorylation and the activation leading to apoptosis. Boussen, et al. concluded that clinical response rate was 78.6% in cohort A (tumors overexpressing with HER2 without coexpression of EGFR) patients. In cohort B (tumors expressing EGFR without HER2 overexpression) the clinical response rate was 71.4%.

Motesanib and paclitaxel: Motesanib is a vascular endothelial growth factor tyrosine kinase inhibitor (VEGFRTKI). VEGF plays an important role in angiogenesis. It is also acting as an antagonist at VEGFR1, VEGFR2, and VEGFR3. The inhibition of kinase is different from that of other VEGFR inhibitors. Martin et al. has reported the overall response rate for motesanib group was 49% and for placebo was 41%, the median progression free survival for motesanib group was 9.5 months.
9.0 months, clinical benefit rate for motesanib was 66%, and for placebo was 18% (Table 2).

**Paclitaxel, bevacizumab, and sunitinib:**
Sunitinib is an oral multi kinase inhibitor that blocks multiple molecular targets that is affecting the growth, proliferation, and metastatic progression of cancer. It increases the circulating vascular endothelial growth factor. Mayer et al. concluded that patients receiving the three drug regimen had unacceptable high level toxicity with discontinuations. Poor tolerability was noted in the regimen with paclitaxel, bevacizumab, and sunitinib.

**Paclitaxel and tegafur:**
Tegafur is a derivative of 5-fluorouracil that inhibits dihydropyrimidine dehydrogenase. Combination therapy or monotherapy with tegafur have a response rate of 6-28%. Villanueva et al. reported that the response duration was 8.4 months, median time to progression was 9.5 months, median overall survival was 23.5 months (Table 2).

**Pegylated liposomal doxorubicin and cyclophosphamide:**
Pegylated liposomal doxorubicin is a formulation of doxorubicin in polyethylene glycol coated liposome. Pegylated formulation prolongs the circulation time and accumulation in the tumor tissues. It helps in the reduction of the side effects as compared with free doxorubicin. Metronomic chemotherapy is the chronic administration of low doses of chemotherapeutic drugs at regular intervals. Dellapasqua et al. have reported that the partial response rate was 62.1% and no grade four toxicity was reported (Table 2).

**Pemetrexed plus doxorubicin followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel:**
Pemetrexed is a folate antimetabolite, which inhibits thymidylate synthase and dihydrofolate reductase. In pretreated metastatic breast cancer single agent pemetrexed with or without vitamin supplementation provided the response rate of 8-28%. Pemetrexed is transported into the cell by the reduced folate carrier and membrane folate binding protein transport systems. In the cell it is converted into the polyglutamated forms which are then retained in the cell. The polyglutamated metabolites have prolonged action in the malignant cells. The drug was approved by USFDA in the year 2010. It is also approved by FDA for maintenance treatment of patients with nonsquamous non-small cell lung cancer whose disease has not progressed after four cycle of first line chemotherapy with platinum based agents. Schneeweiss et al. reported that the pathological complete response with the regimen doxorubicin, pemetrexed, docetaxel was 16.5% and with the regimen doxorubicin, cyclophosphamide, docetaxel was 20.2%. Response rate of doxorubicin, cyclophosphamide was 43.7%, and with doxorubicin, pemetrexed was 40.5% which shows almost similar activity (Table 3).

**Trastuzumab plus docetaxel with trastuzumab plus vinorelbine:**
Vinorelbine is a vinca alkaloid chemotherapeutic drug. It acts synergistically when given in combination with trastuzumab. The antitumor activity of vinorelbine is due to the inhibition of mitosis at the metaphase. It may also interfere with the cyclic AMP, nucleic acid biosynthesis, and inhibit mitotic microtubule formation. Trastuzumab is now approved to be used in combination with cisplatin and fluoropyrimidines for treatment of HER2 over expressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease. HERNATA trial concluded in 2011 reported that there was not much difference on overall survival and median time to progression, response rate between the two treatment arms.

**Trastuzumab and docetaxel with trastuzumab, docetaxel, carboplatin:**
A pivotal phase 3 study conducted by Salmon et al. demonstrated that the combination of trastuzumab and chemotherapy significantly prolonged time to progression and overall survival compared with chemotherapy alone in patients with HER2 positive MBC. Carboplatin predominantly cause interstrand DNA cross links. It nonspecifically affects the cell cycle. Carboplatin is used as first line agent in recurrent ovarian carcinoma. It was approved in 2005 by USFDA. Valero et al. reported that there was no significant difference between docetaxel, trastuzumab (TH) and docetaxel, trastuzumab, carboplatin (TCH). Time to progression in TH regimen was 11.1 months and in TCH was 10.4 months. Response rate in the both regimen was 72%, overall survival rate was 37.1 month in TH regimen, and 37.4 in TCH regimen (Table 2).
CONCLUSION

There are several treatment options for breast cancer like chemotherapy, hormonal therapy, targeted anti-HER2 therapy, and antiangiogenic therapies are available. Now adjuvant and neoadjuvant chemotherapy is advancing as it cures the micro-metastasis leading to better outcomes. There is a significant improvement in the overall survival rate and progression-free survival after the introduction of novel drugs. When selecting a treatment option, the tolerability, efficacy, and mechanism of overcoming resistance have to be considered. The single agent eribulin is a choice of monotherapy for third line monotherapy in advanced breast cancer. Certain drugs like eribulin, ixabepilone with capecitabine and vinorelbine with capcitabine are approved in breast cancer resistant to anthracyclines and taxanes. Fulvestrant a novel single agent drug have considerable progression free survival in ER positive breast cancer. Iniparib in combination with gemcitabine and carboplatin have shown the efficacy in triple negative breast cancer. In HER2 positive breast cancer addition of trastuzumab to neoadjuvant chemotherapy improved overall response rate, reduced progression, relapse and death. Several other treatment options are coming up with maximum clinical efficacy and minimum toxicity level.

REFERENCES


www.ijpsonline.com

Accepted 01 May 2013
Revised 21 April 2013
Received 08 August 2011

Indian J Pharm Sci 2013;75(3):251-261

May - June 2013
Indian Journal of Pharmaceutical Sciences

261